Ocular Therapeutix UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hi. Good morning, everybody. Welcome to the next session at the UBS Global Biopharma Conference in London. I'm Alice Nettleton, one of the U.S. mid biotech analysts at UBS. Happy to introduce Ocular Therapeutix. With us today is Pravin Dugel, CEO. Thank you so much, Pravin, for joining us.
Good to see you. Alice, thanks for having me.
I appreciate your invitation to be here.
Absolutely. Maybe just to level set for the audience, for people who are less familiar with the Ocular story, could you give a quick overview, and then we can move to some Q&A?
Sure. The company is called Ocular Therapeutix. We have a drug that has successfully completed a phase III study. We have been able to show superiority versus an anti-VEGF for the first time ever. We have a result that has a very robust p-value of less than 0.0006, and we're getting ready to submit for approval this quarter. We're on track to do that. The drug is called AXPAXLI. It's a TKI. We believe that we'll be the first and only proper maintenance drug. We have shown in this trial that this drug will last for a year in most patients. Unlike the other drugs that you know about that are bolus injections, and there's a lot of them, whether they be generic or premium drugs, we believe that our drug will be the first and drug that will be approved as a true maintenance drug.
Great. Thank you for the overview. Following the recent competitor phase III miss in wet AMD, there has been some debate among investors around the potential read-through to AXPAXLI, given these drugs are both TKIs. Could you talk about the important differences and why you are still confident in AXPAXLI?
Yeah. The first thing I would say is, look, in anything, I think to classify a class effect for something that fails would mean that we would have no other drugs. We would not have an anti-VEGF, for instance, right now, and we obviously know the anti-VEGFs work extremely well. Remember, one of the first anti-VEGFs to come out there was Macugen, and you know that LUCENTIS is a lot better than Macugen. So if we had a class effect based on Macugen, we would not have any of the other great drugs that we have now. So, that is the first thing. The second thing I would tell you is that, I do not necessarily enjoy speaking about other people or failures, but we absolutely predicted that this was going to happen two and a half years ago. We told you exactly what was going to happen with EyePoint.
We said that their TKI was an inferior TKI as well as VEGF suppression is concerned. We know that from a lot of studies that have already been done that we have cited. We said that their delivery system was inferior. Very, very importantly, and this is extremely important, we said that they had really put no thought into patient selection, and patient selection was absolutely key. We have spent a great deal of time, a great deal of thought selecting the proper patients in a bespoke manner for each study, which they did not do, and we can talk about that in detail. So everything that happened, we absolutely predicted. We predicted that that drug would have a signal, and it does, and we predicted that it would miss the primary endpoint, which it did. It absolutely has no effect on what we are doing.
We hit a superiority endpoint against a very, very good drug in EYLEA with a robust p-value. We have shown everything that we possibly can in our SOL-1 study, and has nothing to do with the class effect whatsoever. Their failure has everything to do with selecting a weaker TKI in a worse format with no thought to patient selection whatsoever.
Do you want to expand on that point then about patient selection and what is different about your trial?
Yeah, I will be happy to. So, I think this is, in my field in retina, I would say that this is probably the most underappreciated thing there is, and let me explain. We are at least 50 to 75 years behind oncology or rheumatology or immunology. We have absolutely no disease stratification whatsoever. We have no biomarker of disease response, whether that biomarker be genetic or anatomic. So, when people come in, they look exactly the same. They respond in a very diverse manner, but they look exactly the same. We have no way of differentiating that. I will give you an example. If I were to come to you and say, "Alice, I have a drug for colon cancer," you would just laugh. You would say, "What kind of colon cancer? What stage? What grade?" Et cetera, et cetera. We have no way of differentiating that.
However, we can still come to you and say, "Look, we have a drug for wet macular degeneration," yet we know that there are some patients with wet macular degeneration, even with regular LUCENTIS, that require treatment maybe once every six months. Others may require treatment once every two weeks. We have no idea how to differentiate them, so we do something called treat and extend, which is essentially trial and error. We go ahead and inject, we see how they do, and then we figure out little by little what cadence to inject them in. You can imagine that when you do huge studies like we used to do for ANCHOR and MARINA or VIEW 1 and VIEW 2, where we had 2,000, 3,000 patients, these kind of imbalances may work themselves out just because of the large sample size.
But when we are doing smaller studies like we are doing now, these imbalances can go ahead and completely upend the study. So that is why patient selection is extraordinarily important. What we did in SOL-1, for instance, was say we needed patients who were going to lose vision, because the delta was based on maintenance of vision. So, we specifically selected patients who were anti-VEGF dependent. We gave two injections of EYLEA. We only selected those patients that either became 20/20 or improved by 10 letters or more, and then we stopped injecting them with the anti-VEGF. We proved they were anti-VEGF dependent, we took away the anti-VEGF, and we allowed them to lose vision once to create that delta, and we succeeded. And that is the opposite of what we are doing in our second study called SOL-R. Here, we want absolute stability.
What we're doing there is giving three loading injections of EYLEA, and then we're waiting to observe the patient for two months, and that's never been done before. We're simply observing the patients for any fluctuations in the OCT, and if they're unstable, we're weeding them out, and then after that, two more injections, and only then are we randomizing them. We're trying to do our best to de-risk this patient population by ensuring absolute stability. That much thought has been put into proper patient selection in a bespoke manner for each study, and I don't know of any other clinical trial that's doing that.
Moving on to the regulatory side, you've obviously had a successful SOL-1 trial, and you're hoping to submit your NDA soon, or perhaps that's already in process. Can you provide an update on that?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
